The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.

Author

  • Göran B Jönsson
  • Johan Staaf
  • Johan Vallon-Christersson
  • Markus Ringnér
  • Sofia Gruvberger
  • Lao Saal
  • Karolina Holm
  • Cecilia Hegardt
  • Adalgeir Arason
  • Rainer Fagerholm
  • Camilla Olsson
  • Dorthe Grabau
  • Ellinor Johnsson
  • Kristina Lövgren
  • Linda Magnusson
  • Paivi Heikkilä
  • Bjarni A Agnarsson
  • Oskar Th Johannsson
  • Per Malmström
  • Mårten Fernö
  • Håkan Olsson
  • Niklas Loman
  • Heli Nevanlinna
  • Rosa Bjork Barkardottir
  • Åke Borg
Show all

Summary, in English

Breast tumors from BRCA1 germ line mutation carriers typically exhibit features of the basal-like molecular subtype. However, the specific genes recurrently mutated as a consequence of BRCA1 dysfunction have not been fully elucidated. In this study, we utilized gene expression profiling to molecularly subtype 577 breast tumors, including 72 breast tumors from BRCA1/2 mutation carriers. Focusing on the RB1 locus, we analyzed 33 BRCA1-mutated, 36 BRCA2-mutated and 48 non-BRCA1/2-mutated breast tumors using a custom-designed high-density oligomicroarray covering the RB1 gene. We found a strong association between the basal-like subtype and BRCA1-mutated breast tumors and the luminal B subtype and BRCA2-mutated breast tumors. RB1 was identified as a major target for genomic disruption in tumors arising in BRCA1 mutation carriers and in sporadic tumors with BRCA1 promoter-methylation, but rarely in other breast cancers. Homozygous deletions, intragenic breaks, or microdeletions were found in 33% of BRCA1-mutant tumors, 36% of BRCA1 promoter-methylated basal-like tumors, 13% of non-BRCA1 deficient basal-like tumors, and 3% of BRCA2-mutated tumors. In conclusion, RB1 was frequently inactivated by gross gene disruption in BRCA1-related hereditary breast cancer and BRCA1-methylated sporadic basal-like breast cancer, but rarely in BRCA2-hereditary breast cancer and non-BRCA1-deficient sporadic breast cancers. Together, our findings demonstrate the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1-status.

Department/s

  • Breastcancer-genetics
  • Tumor microenvironment
  • Division of Hematology and Clinical Immunology
  • Division of Clinical Genetics
  • Familial Breast Cancer
  • EpiHealth: Epidemiology for Health
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2012

Language

English

Pages

4028-4036

Publication/Series

Cancer Research

Volume

72

Issue

16

Document type

Journal article

Publisher

American Association for Cancer Research Inc.

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Familial Breast Cancer

ISBN/ISSN/Other

  • ISSN: 1538-7445